Artesunate Ameliorates Functional Limitations in Freund’s Complete Adjuvant-Induced Monoarthritis in Rat by Maintaining Oxidative Homeostasis and Inhibiting COX-2 Expression
- 290 Downloads
Drugs exhibiting anti-inflammatory and analgesic properties have been clinically used in the management of pain and impairment of joint functions in arthritis. In view of available studies on the beneficial effect of artesunate in various inflammatory conditions, the present study was carried out to evaluate its efficacy in ameliorating functional limitations of arthritis and to understand the underlying mechanisms. The study was carried out in rat model of Freund’s complete adjuvant-induced monoarthritis where artesunate was found to produce a dose-dependent reduction in joint inflammation, improvement in functional parameters like stair climbing ability, motility, and suppression of mechanical allodynia at the doses of 50 and 150 mg/kg. Our study shows that protection afforded by artesunate was brought about by decreasing the levels of nitric oxide, influx of neutrophils, maintenance of oxidative homeostasis, inhibition of COX-2 expression, and apoptosis. Further, histological analysis of the arthritic joints also substantiated the anti-inflammatory property of artesunate. Thus, our study shows that artesunate has a potential for use in the treatment of arthritis.
KEY WORDSartesunate arthritis COX-2 expression inflammatory hyperalgesia oxidative homeostasis
This work was funded by a research grant from All India Institute of Medical Sciences, New Delhi, India (A-059).
Conflict of Interest
The authors declare that there is no conflict of interest.
- 7.Salliot, C., A. Finckh, W. Katchamart, Y. Lu, Y. Sun, C. Bombardier, and E. Keystone. 2011. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 70: 266–271.CrossRefPubMedGoogle Scholar
- 9.Graziose, R., M.A. Lila, and I. Raskin. 2010. Merging traditional Chinese medicine with modern drug discovery technologies to find novel drugs and functional food. Curr Drug Discov Technol 7: 2–12.Google Scholar
- 11.Li, B., R. Zhang, J. Li, L. Zhang, G. Ding, P. Luo, S. He, Y. Dong, W. Jiang, Y. Lu, H. Cao, J. Zhang, and H. Zhou. 2008. Antimalarial artesunate protects sepsis model mice against heat-killed Escherichia coli challenge by decreasing TLR4, TLR9 mRNA expressions and transcription factor NF-kappa B activation. Int Immunopharmacol 8: 379–389.Google Scholar
- 12.Li, B., J. Li, X. Pan, G. Ding, H. Cao, W. Jiang, J. Zheng, and H. Zhou. 2010. Artesunate protects sepsis model mice challenged with Staphylococcus aureus by decreasing TNF- alpha release via inhibition of TLR2 and Nod2 mRNA expressions and transcription factor NF-kappaB activation. Int Immunopharmacol 10: 344–350.CrossRefPubMedGoogle Scholar
- 13.He, Y., J. Fan, H. Lin, X. Yang, Y. Ye, L. Liang, Z. Zhan, X. Dong, L. Sun, and H. Xu. 2011. The anti-malaria agent artesunate inhibits expression of vascular endothelial growth factor and hypoxia-inducible factor-1α in human rheumatoid arthritis fibroblast-like synoviocyte. Rheumatol Int 31: 53–60.CrossRefPubMedGoogle Scholar
- 14.Li, Y., S. Wang, Y. Wang, C. Zhou, G. Chen, W. Shen, C. Li, W. Lin, S. Lin, H. Huang, P. Liu, and X. Shen. 2013. Inhibitory effect of the antimalarial agent artesunate on collagen-induced arthritis in rats through nuclear factor kappa B and mitogen-activated protein kinase signaling pathway. Transl Res 161: 89–98.CrossRefPubMedGoogle Scholar
- 15.Kumar, V.L., B. Guruprasad, and P. Chaudhary. 2014. Antimalarial drug artesunate affords protection against carrageenan induced acute inflammation in rat. Biocell (in press).Google Scholar
- 22.Bradley, P.P., D.A. Preibat, R.D. Christensen, and G. Rothstein. 1982. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78: 206–209.Google Scholar
- 30.Nakao, S., Y. Ogtata, E. Shimizu, M. Yamazaki, S. Furuyama, and H. Sugiya. 2002. Tumor necrosis factor alpha (TNF-alpha)-induced prostaglandin E2 release is mediated by the activation of cyclooxygenase-2 (COX-2) transcription via NFkappaB in human gingival fibroblasts. Mol Cell Biochem 238: 11–18.CrossRefPubMedGoogle Scholar
- 32.Telleria-Diaz, A., M. Schmidt, S. Kreusch, A.K. Neubert, F. Schache, E. Vazquez, H. Vanegas, H.G. Schaible, and A. Ebersberger. 2010. Spinal antinociceptive effects of cyclooxygenase inhibition during inflammation: Involvement of prostaglandins and endocannabinoids. Pain 148: 26–35.CrossRefPubMedGoogle Scholar
- 34.Lemos, H.P., R. Grespan, S.M. Vieira, T.M. Cunha, W.A. Verri Jr., K.S. Fernandes, F.O. Souto, I.B. McInnes, S.H. Ferreira, F.Y. Liew, and F.Q. Cunha. 2009. Prostaglandin mediates IL-23/IL-17-induced neutrophil migration in inflammation by inhibiting IL-12 and IFNgamma production. Proc Natl Acad Sci U S A 106: 5954–5959.Google Scholar
- 43.Adán, N., J. Guzmán-Morales, M.G. Ledesma-Colunga, S.I. Perales-Canales, A. Quintanar-Stéphano, F. López-Barrera, I. Mendez, B. Moreno-Carranza, J. Triebel, N. Binart, G. Martinez de la Escalera, S. Thebault, and C. Clapp. 2013. Prolactin promotes cartilage survival and attenuates inflammation in inflammatory arthritis. J Clin Invest 123: 3902–3913.Google Scholar